Hypersensitivity to opiates; upper airway obstruction; acute asthma; diarrhea due to poisoning or toxins.
2009 Wolters Kluwer Health. More... More FDA updates.
Extensively metabolized in the liver to noroxycodone (a major metabolite), oxymorphone, and their glucuronides.
Oxecta - Tablets 5 mg - Tablets 7.5 mg.
Peak plasma oxycodone and noroxycodone concentrations 50% and 20% higher; AUC values are 95% and 65% higher, respectively. Oxymorphone peak plasma concentration and AUC values are lower by 30% and 40%. The t ½ elimination for oxycodone is increased by 2.3 h.
Hypotension; orthostatic hypotension; bradycardia; tachycardia.
Subscribe to receive notifications whenever new articles are published.
Store at room temperature in tightly closed container; protect from light. Additive CNS depression.
Roxicodone - Tablets 5 mg - Tablets 15 mg - Tablets 30 mg.
Use with caution in elderly and debilitated patients and patients with myxedema, acute alcoholism, acute abdominal conditions, ulcerative colitis, decreased respiratory reserve, head injury or increased intracranial pressure, hypoxia, supraventricular tachycardia, depleted blood volume, or circulatory shock. Has abuse potential.
Dosage reduction may be necessary.
Oxycodone - Tablets 10 mg - Tablets 20 mg - Capsules 5 mg - Solution, oral 5 mg/5 mL - Solution, concentrate, oral 20 mg/mL.
Excreted in breast milk.
High oral availability due to low presystemic or first-pass metabolism. Exhibits a biphasic absorption pattern. The immediate-release oral bioavailability is 100%. The oral bioavailability is 60% to 87%. Peak plasma concentration increased by 25% with a high fat meal. Once absorbed it is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain.
Tolerance; psychological and physical dependence with chronic use.
provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated Mar 30th, 2016), Cerner Multum (updated Apr 1st, 2016), Wolters Kluwer (updated Apr 1st, 2016) and others. To view content sources and attributions, please refer to our editorial policy.
PO 10 to 30 mg every 4 h (5 mg every 6 h for OxyIR, oxycodone immediate-release capsules, Oxydose, and OxyFAST ) as needed.
The Vd is 2.6 L/kg (IV). It is found in breast milk.
Respiratory depression; laryngospasm; depression of cough reflex.
Nausea; vomiting; constipation; abdominal pain.
Dosage reduction may be necessary.
Relief of moderate to moderay severe pain.
Increased amylase and lipase may occur up to 24 h after administration.
We comply with the HONcode standard for trustworthy health information - verify here.
OxyContin - Tablets, controlled-release 10 mg - Tablets, controlled-release 15 mg - Tablets, controlled-release 20 mg - Tablets, controlled-release 30 mg - Tablets, controlled-release 40 mg - Tablets, controlled-release 60 mg - Tablets, controlled-release 80 mg.
4 to 6 h.
15 to 30 min. 1 h.
Miosis, respiratory depression, CNS depression (somnolence progressing to stupor or coma), circulatory collapse, seizures, cardiopulmonary arrest, death.
Lightheadedness; dizziness; sedation; disorientation; incoordination. Sweating; pruritus; urticaria.
For less than 60 mL/min, higher peak plasma oxycodone (50%), and noroxycodone (20%), higher AUC for oxycodone (60%), noroxycodone (50%), oxymorphone (40%). There is an increased t ½ of oxycodone elimination of only 1 h.
The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.
PO 10 to 160 mg twice daily (80 and 160 mg controlled-release tablets are for use in opioid-tolerant patients only).
Controlled release is for management of moderate to severe pain with around-the-clock dosing. Not intended for as-needed use. Use 80 and 160 mg tablets in opioid tolerant patients only. Respiratory depression reported when used in opioid-naive patients. Swallow tablets whole. Do not crush, chew, or break; may result in potential fatal dose of oxycodone. Category C.
Urinary retention or hesitancy.
Individualize dosing regimen for each patient.
Excreted through the urine, with less than 19% as free oxycodone, less than 50% as conjugated oxycodone, and less than 14% as conjugated oxymorphone. The t ½ for immediate release is 0.4 h. Cl is 0.8 L/min. Elimination on t 1/2 is 3.2 h (immediate release).
Not recommended for children.
Pronunciation: OX-ee-KOE-dohn HIGH-droe-KLOR-ide Class: Opioid analgesic.
Relieves pain by stimulating opiate receptors in CNS; may cause respiratory depression, peripheral vasodilation, inhibition of intestinal peristalsis, sphincter of Oddi spasm, stimulation of chemoreceptors that cause vomiting and increased bladder tone.Oxycodone hydrochloride